Investor Relations

Upcoming Events

Lake Street Capital Markets BIG6 Conference

Piper Sandler Heartland Summit

13th Annual Craig-Hallum Alpha Select Conference

Most Recent Business Quarterly Update

View Q2 2022 Update

Company Overview

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company developing recombinant proteins to improve the lives of patients who experience a stroke or recurrent strokes and kidney diseases.

Investor Contact Information

Company

DiaMedica Therapeutics, Inc.
Two Carlson Parkway,
Suite 260
Minneapolis, MN 55447

Investor Relations

DiaMedica Therapeutics Inc.
Scott Kellen
Chief Financial Officer
T: (763) 496-5192
F: (763) 710-4456
skellen@diamedica.com